Berkshire Hathaway -- Quarterly Update -- 4Q21

Link here.

• Berkshire Hathaway's 13F stock portfolio value increased from ~$293B to ~$331B.
• Their largest three holdings are at over two-thirds of the entire portfolio.
• Berkshire Hathaway increased Chevron while reducing AbbVie, Marsh & McLennan, Bristol-Myers Squibb, Visa, and Royalty Pharma during the quarter. They also dropped Teva.

Bank of New York Mellon Corp.: BK is a 1.27% of the 13F portfolio stake. The bulk of the original position was purchased in Q2 2012 at prices between $19.50 and $25. Recent activity follows: 2017 saw a ~180% increase at prices between $43.50 and $55 while 2018 saw another one-third increase at prices between $44.50 and $58.50. The stock currently trades at $62.23. Berkshire’s cost-basis on BK is ~$46 per share and ownership stake is 8.4%.

This article concerns only 13F filings. 

Annual report for BRK is expected to be released on/about February 26, 2022.